Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-09
2009-06-09
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S563000, C514S238800, C514S237800, C514S323000, C514S424000, C514S470000, C544S144000, C544S158000, C546S201000, C548S484000, C548S542000, C548S950000
Reexamination Certificate
active
07544676
ABSTRACT:
Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.
REFERENCES:
patent: 4029787 (1977-06-01), Sturm et al.
patent: 4550179 (1985-10-01), Perrot et al.
patent: 7297796 (2007-11-01), Dolle et al.
patent: 2004/017920 (2004-03-01), None
patent: WO2005/066126 (2005-07-01), None
patent: WO2006/044654 (2006-04-01), None
Cannabinoid receptors, Wikipedia.
Cited ref—STN preliminary search—11558332.
Bhargava, H.N., et al., “Effect of nitric oxide synthases inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5enkephalin and morphine in the mouse,”Neuropeptides, 1996, 30(3), 219-223.
Bilsky, E.J., et al., “Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice,”J. Pharmacol. Exp. Ther., 1996, 277(1), 484-490.
Cheng, Y.-C., et al., “Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol., 1973, 22, 3099-3108.
Compton, D.R., et al., “Cannabinoid behaviors: specific versus nonspecific actions,”Marijuana: An International Research Report, 1987, 7, 213-218.
Costa, A. et al., “A1PO4-A12O3Promoted Cyclodehydration of Diols,”Synthetic Communications, 1987, 17(11), 1373-1376.
DeLean, A.P., et al., “Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves,”Am. J. Physiol., 1978, 235, E97-E102.
Dourish, C.T., et al., “Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718,”Eur. J. Pharmacol., 1988, 147, 469-472.
Flippin, L.A. et al., “A Convenient Method for the Reduction of Ozonides to Alcohols with Borane-Dimethyl Sulfide Complex,”Journal of Organic Chemistry, 1989, 54(6), 1430-2.
Gill, E.W., et al., “Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice-correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide,”Biochem. Pharmacol., 1972, 21, 2237-2248.
Gill, E.W., et al., “Preliminary experiments on the chemistry and pharmacology of cannabis,”Nature, 1970, 228, 134-136.
Howlett, A.C., et al., “International union of pharmacology. XXVII.. Classification of cannabinoid receptors,”Pharmacological Reviews, 2002, 54(2), 161-202.
Idris, A.I., et al., “Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors,”Nature Medicine, 2005, 11(7), 774-779.
Iwamura, H., et al., “In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2receptor,”J. Pharm. Exp. Ther., 2001, 296(2), 420-425.
Jain, K.K., “A guide to drug evaluation for chronic pain,”Emerging Drugs, 2000, 5(2), 241-257.
Lavey, B.J., et al., “Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies,”Bioorg.&Med. Chem. Lett, 2005, 15, 783-786.
Lunn, C.A., et al., “Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial biological characterization,”ICRS 15thAnnual Symposium of the Cannabinoids, Clearwater Beach, FL, Jun. 24-27, 2005, p. 3 Abstract.
Malan, T.P., Jr., et al., “CB2cannabinoid receptor agonists: pain relief without psychoactive effects?,”Curr. Opin. Pharm., 2003, 3, 62-67.
Mao, J., et al., “Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats,”Pain, 1996, 67, 361-368.
Mechoulam, R., (Ed.),Cannabinoids as therapeutic agents, CRC Press, Boca Raton, FL, Jul, 1986, Chapter 1, 1-19.
Nichols, M.L., et al., “Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy,”Pain, 1997, 69, 317-322.
Olah, G.A., et al., “Synthetic Methods and Reactions: 991. Preparation of Cyclic Ethers over Superacidic Perfluorinated Reinsulfonic Acid (Nafion-H) Catalyst,”Synthesis, 1981, 474-476.
Parolaro, D., “Presence and functional regulations of cannabinoid receptors in immune cells,”Life Sci., 1999, 65(6/7), 637-644.
Pertwee, R.B., “Pharmacology of cannabinoid receptor ligands,”Current Medicinal Chem., 1999, 6, 635-664.
Pertwee, R.G., “Cannabinoid receptors and pain,”Prog. in Neurobiol., 2001, 63, 569-611.
Pertwee, R.G., “The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice,”Br. J. Pharmacology, 1972, 46, 753-763.
Rice, A.S., “Cannabinoids and pain,”Curr. Opin, Investig. Drugs, 2001, 2(3), 399-414.
Rinaldi-Carmona, M., et al., “SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor,”J. of Pharmacology&Experimental Therapeutics, 1998, 284(2), 644-650.
Dolle Roland E.
Worm Karin
Adolor Corporation
Cherry David A.
Chu Yong
Feldman Gale P.A.
Shiao Rei-Tsang
LandOfFree
Sulfamoyl benzamides and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfamoyl benzamides and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamoyl benzamides and methods of their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131201